Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221877 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Effect of KarXT on Urological Safety
A Phase 4 study of Schizophrenia, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 14
- Study locations
NCT07221877 is a Phase 4 study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 14 study locations across 8 states.
The verdict
NCT07221877, a Phase 4 study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
Conditions Studied
Interventions
- DRUG Xanomeline/trospium chloride
Study Locations (14)
California
- Local Institution - 0007 - Bellflower
- Local Institution - 0009 - Culver City
- CenExel CNS - Garden Grove - Garden Grove
- Local Institution - 0016 - Orange
Florida
- Local Institution - 0003 - Miami
- Local Institution - 0004 - Stuart
Illinois
- Uptown Research Institute - Chicago
- Local Institution - 0010 - Chicago
Texas
- Local Institution - 0001 - Austin
- InSite Clinical Research - DeSoto
Arkansas
- Local Institution - 0017 - Little Rock
Nevada
- Local Institution - 0013 - Las Vegas
New Jersey
- Hassman Research Institute Marlton Site - Marlton
Pennsylvania
- Adams Clinical Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221877
The ClinicalTrials.gov registry entry for NCT07221877 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Xanomeline/trospium chloride is the first listed.
NCT07221877 reports 14 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT07221877 about?
NCT07221877 is a clinical study titled "A Study to Evaluate the Effect of KarXT on Urological Safety". The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
What is the current status of trial NCT07221877?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-01-20. Estimated completion is 2027-12-30.
What conditions does trial NCT07221877 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07221877?
The interventions under investigation include: Xanomeline/trospium chloride (DRUG).
Who is sponsoring clinical trial NCT07221877?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221877 being conducted?
This trial has 14 study locations across Arkansas, California, Florida, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.